Exelixis
EXEL
#1694
Rank
S$15.47 B
Marketcap
S$57.49
Share price
-0.02%
Change (1 day)
19.90%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of September 2025 : S$0.22 Billion

According to Exelixis's latest financial reports the company's total debt is S$0.22 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2025)

Total debt by year

Year Total debt Change
2024-12-31S$0.25 B3.4%
2023-12-31S$0.25 B-1.6%
2022-12-31S$0.25 B267.8%
2021-12-31S$69.31 M6.74%
2020-12-31S$64.93 M0.32%
2019-12-31S$64.72 M217.64%
2018-12-31S$20.37 M1.99%
2017-12-31S$19.97 M-92.7%
2016-12-31S$0.27 B-53.7%
2015-12-31S$0.59 B25.34%
2014-12-31S$0.47 B7.21%
2013-12-31S$0.43 B7.15%
2012-12-31S$0.41 B74.66%
2011-12-31S$0.23 B-12.46%
2010-12-31S$0.26 B140.23%
2009-12-31S$0.11 B-33.58%
2008-12-31S$0.16 B-3.75%
2007-12-31S$0.17 B-6.26%
2006-12-31S$0.18 B-24.73%
2005-12-31S$0.24 B3.09%
2004-12-31S$0.24 B27.37%
2003-12-31S$0.18 B47.12%
2002-12-31S$0.12 B41.59%
2001-12-31S$90.6 M249.68%
2000-12-31S$25.91 M17.01%
1999-12-31S$22.14 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
GlaxoSmithKline
GSK
S$30.92 B 13,422.38%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
S$33.08 B 14,368.36%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
S$53.61 B 23,346.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
S$66.14 B 28,824.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
S$70.73 B 30,833.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
S$59.34 B 25,851.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
S$78.85 B 34,382.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
S$2.55 M-98.88%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
S$50.12 M-78.08%๐Ÿ‡บ๐Ÿ‡ธ USA